Han Jung-Yeol, Nava-Ocampo Alejandro A, Kim Tae-Jin, Shim Jae-Uk, Park Chong-Taik
Department of Obstetrics and Gynecology, Samsung Cheil Hospital and Women's Health-Care Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Reprod Toxicol. 2005 Mar-Apr;19(4):557-61. doi: 10.1016/j.reprotox.2004.11.002.
Bleomycin plus etoposide and cisplatin seem to be a promising alternative for women with ovarian cancer. We are reporting two cases with favorable pregnancy outcome after exposure to these chemotherapeutic agents at the second and third trimesters of pregnancy. A pregnant woman with a stage Ic yolk-sac tumor underwent a right oophorectomy with omentectomy, and received five cycles of bleomycin, etoposide and cisplatin from the 22nd week of pregnancy until delivery. The second case was a pregnant woman with a stage Ia immature teratoma who underwent right salpingo-oophorectomy and received two cycles of bleomycin, etoposide and cisplatin starting at 30th week of pregnancy. The two patients did not have any evidence of recurrence of ovarian cancer for 6 and 2 years, respectively. Their babies did not have any evidence of minor or major malformations, and showed normal neurological development at 6 and 2 years of follow-up, respectively.
博来霉素联合依托泊苷和顺铂似乎是卵巢癌女性患者的一种有前景的替代治疗方案。我们报告了两例在妊娠中期和晚期接触这些化疗药物后获得良好妊娠结局的病例。一名患有Ⅰc期卵黄囊瘤的孕妇接受了右侧卵巢切除术及大网膜切除术，并在妊娠22周直至分娩期间接受了五个周期的博来霉素、依托泊苷和顺铂治疗。第二例是一名患有Ⅰa期未成熟畸胎瘤的孕妇，她接受了右侧输卵管卵巢切除术，并在妊娠30周开始接受了两个周期的博来霉素、依托泊苷和顺铂治疗。这两名患者分别在6年和2年内没有卵巢癌复发的迹象。她们的婴儿分别在随访6年和2年时没有任何轻微或严重畸形的迹象，并且神经发育正常。
